2 minute read
Prostate
The prostate subcommittee continues to generate copious activity.
Firstly a big THANK YOU to all the investigators and site staff for your ongoing effort and contributions to the ENZAMET and ENZARAD trials. Both trials have performed extremely well with 379 and 146 patients recruited respectively globally, with the highest recruiters in the last quarter for ENZAMET being from Chris O’Brien Lifehouse, Monash Medical Centre Moorabbin and Adelaide and Meath Hospital (Ireland). For ENZARAD, Auckland Hospital, congratulations and well done to you all! We anticipate recruitment to continue to increase in the New Year with additional sites coming on board in Ireland and the United Kingdom for both trials and in Canada for ENZAMET. Please promote both trials at your MDT meetings, consider rescreening screen failures and perhaps have the eligibility criteria on hand when discussing or seeing patients.
The Pain-Free TRUS-B study will be activated shortly across several centres. This is a randomised trial of inhaled Penthrox in addition to local anaesthetic for transrectal prostate biopsy. It has funding through the Priority-driven Collaborative Cancer Research Scheme (PdCCRS) (Cancer Australia and Prostate Cancer Foundation of Australia). We look forward to announcing it has opened in a site near you soon.
We held a very productive all-day Concept Development Workshop on 23 September at Lifehouse in Sydney. A number of new concepts were discussed across the different disease settings. Several of these concepts will continue to be developed by members with support from the broader subcommittee. A summary document of the day will be circulated shortly.
ANZUP also held its first highly successful GU Preceptorship in prostate cancer in Melbourne in November. The feedback from the ~40 participants was overwhelmingly positive, with pretty much everyone asking when we are planning our next one! We look forward to sharing a summary of the formal feedback once we have received and collated it over the next week or two. Our membership continues to grow (overall ANZUP membership 961 with the prostate subcommittee standing at 323 members) with a diverse range of skills represented. I remind everyone to encourage any colleagues with a prostate cancer interest to join and contribute.
I would like to take the opportunity to thank my deputy chair, Carmel Pezaro, for her support and all those members who continue to turn up and contribute to the prostate teleconferences.
Finally I wish you and your families a very Merry Christmas and a safe and happy holiday season.
SCOTT WILLIAMS Chair, Prostate Cancer Subcommittee
Did you know ANZUP is now tweeting to over 1000 followers?
Our community are sharing trial updates and news across Twitter. We’re always interested in retweeting your thoughts, stories and insights with the rest of our followers. At our ASM in July our #ANZUP15 thread made over 1.2 million impressions in 4 days. Follow @ANZUPtrials and start communicating with leading professionals today.
